Article of Significant Interest Selected from This Issue by the Editors

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-11-01 DOI:10.1128/cvi.00272-17

引用次数: 0

Abstract

Effective Nanovaccines Protect against Lethal Burkholderia pseudomallei Infection Burkholderia pseudomallei, causative agent of melioidosis, exhibits high morbidity and mortality in humans. There are currently no vaccines available, and treatment options are limited. In the study by Muruato et al. (e00206-17), reverse vaccinology methods were used to identify novel, seroreactive Burkholderia antigens. Nanovaccines containing these proteins and Burkholderia lipopolysaccharide (LPS) generated high anti-protein and anti-LPS antibody titers in mice. One of these novel proteins, FlgL, provided 90% protection against lethal B. pseudomallei respiratory infection. Importantly, animals demonstrated a significant decrease in lung bacterial colonization compared to controls. These findings support further testing and development of nanovaccines against melioidosis.

查看原文本刊更多论文

由编辑从本期杂志中选出的具有重要意义的文章

伪伯克氏菌是类鼻疽病的病原体，在人类中具有很高的发病率和死亡率。目前没有可用的疫苗，治疗选择也有限。在Muruato等人(e00206-17)的研究中，使用反向疫苗学方法鉴定了新的、血清反应性伯克氏菌抗原。含有这些蛋白和伯克霍尔德氏菌脂多糖(LPS)的纳米疫苗在小鼠体内产生了高的抗蛋白和抗LPS抗体滴度。其中一种新蛋白FlgL对致命性假芽孢杆菌呼吸道感染提供了90%的保护。重要的是，与对照组相比，动物肺部细菌定植明显减少。这些发现支持了针对类鼻疽病的纳米疫苗的进一步测试和开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.